東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pulmonary tuberculosis and its preve...

Saito, Takefumi.

FindBook

Google Book

Amazon

博客來

Pulmonary tuberculosis and its prevention

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Pulmonary tuberculosis and its prevention/ edited by Takefumi Saito, Masahiro Narita, Charles L. Daley.
其他作者:	Saito, Takefumi.
出版者:	Singapore :Springer Nature Singapore : : 2022.,
面頁冊數:	viii, 294 p. :ill. (some col.), digital ;24 cm.
內容註:	Part I. Epidemiology and Pathogenesis -- Chapter 1. Epidemiology -- Chapter 2. Immunology -- Chapter 3. Impact of Biologic and JAK Inhibitor Therapies on TB: How do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB? -- Chapter 4. Advances in Mycobacterial Laboratories: What is the latest laboratory approach to diagnose and manage pulmonary tuberculosis? -- Part II Pulmonary Tuberculosis -- Chapter 5. Advances in Diagnostics of Pulmonary tuberculosis: What is the Latest Approach to Diagnose Pulmonary TB? -- Chapter 6. HRCT diagnosis of pulmonary tuberculosis: Microlesions -- Chapter 7. Advances in Treatment of Drug Resistant Pulmonary TB: What is the latest approach to treat drug-resistant pulmonary TB? -- Chapter 8. The Role of Surgical Interventions for Pulmonary TB: What is the Role of Surgical Intervention in Pulmonary TB? -- Part III Latent TB Infection: TB Prevention -- Chapter 9. Advances in Diagnosis of Latent TB Infection: What is the Latest Approach to Diagnose Latent TB Infection to Prevent TB? -- Chapter 10. Advances in Treatment of Latent TB Infection: What is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB? -- Part IV Research Areas -- Chapter 11. TB vaccines: What Type of TB Vaccines are Studied and will be Available in the Future? -- Chapter 12. Clinical Trials of Pulmonary TB: Challenges and Opportunities -- Chapter 13. Contributions of Japanese Scholars to Advances in Clinical Tuberculosis Management: In TB World, What Kind of Achievements are Accomplished by Japanese Researchers?
Contained By:	Springer Nature eBook
標題:	Tuberculosis. -
電子資源:	https://doi.org/10.1007/978-981-19-3995-2
ISBN:	9789811939952

Pulmonary tuberculosis and its prevention
Pulmonary tuberculosis and its prevention[electronic resource] /edited by Takefumi Saito, Masahiro Narita, Charles L. Daley. - Singapore :Springer Nature Singapore :2022. - viii, 294 p. :ill. (some col.), digital ;24 cm. - Respiratory disease series: diagnostic tools and disease managements,2509-5560. - Respiratory disease series: diagnostic tools and disease managements..

Part I. Epidemiology and Pathogenesis -- Chapter 1. Epidemiology -- Chapter 2. Immunology -- Chapter 3. Impact of Biologic and JAK Inhibitor Therapies on TB: How do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB? -- Chapter 4. Advances in Mycobacterial Laboratories: What is the latest laboratory approach to diagnose and manage pulmonary tuberculosis? -- Part II Pulmonary Tuberculosis -- Chapter 5. Advances in Diagnostics of Pulmonary tuberculosis: What is the Latest Approach to Diagnose Pulmonary TB? -- Chapter 6. HRCT diagnosis of pulmonary tuberculosis: Microlesions -- Chapter 7. Advances in Treatment of Drug Resistant Pulmonary TB: What is the latest approach to treat drug-resistant pulmonary TB? -- Chapter 8. The Role of Surgical Interventions for Pulmonary TB: What is the Role of Surgical Intervention in Pulmonary TB? -- Part III Latent TB Infection: TB Prevention -- Chapter 9. Advances in Diagnosis of Latent TB Infection: What is the Latest Approach to Diagnose Latent TB Infection to Prevent TB? -- Chapter 10. Advances in Treatment of Latent TB Infection: What is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB? -- Part IV Research Areas -- Chapter 11. TB vaccines: What Type of TB Vaccines are Studied and will be Available in the Future? -- Chapter 12. Clinical Trials of Pulmonary TB: Challenges and Opportunities -- Chapter 13. Contributions of Japanese Scholars to Advances in Clinical Tuberculosis Management: In TB World, What Kind of Achievements are Accomplished by Japanese Researchers?

Every year, 10 million people fall ill with tuberculosis (TB) in the world, and of those, 1.5 million people die even though it is a preventable and curable disease. As a result, TB remains the world's leading infectious cause of death. On the other hand, in industrialized countries, the TB incidence has fallen to a historic low, and clinicians' experience with TB diminished significantly in recent years. Additional challenges for clinicians include atypical presentation of TB in the immunocompromised, especially among the elderly, and an increasing number of patients with drug-resistant TB. Delayed diagnosis of TB leads to the spread of TB including nosocomial transmission because TB is an air-borne infectious disease, and suboptimal treatment can result in development of drug resistance. Furthermore, treatment of latent TB infection (LTBI) can prevent future TB cases but it has been under-utilized despite recent innovations in diagnosis and treatment regimens of LTBI. This book focuses on advances in diagnostic tools and treatment for both TB disease and latent TB infection. Each chapter/topic is written by one of the top TB experts in the field and the authors are from Japan and the US. Pulmonary Tuberculosis and its Prevention offers up-to-date information that can be incorporated into a busy practice of clinicians while they can appreciate broad international perspectives and gain in-depth knowledge on TB.

ISBN: 9789811939952

Standard No.: 10.1007/978-981-19-3995-2doiSubjects--Topical Terms:

808530
Tuberculosis.

LC Class. No.: RC311.1 / .P85 2022

Dewey Class. No.: 616.995

Pulmonary tuberculosis and its prevention
LDR:04119nmm a2200337 a 4500 001 2305134
003 DE-He213
005 20221020170725.0
006 m d
007 cr nn 008maaau
008 230409s2022 si s 0 eng d
020 $a 9789811939952 $q (electronic bk.)
020 $a 9789811939945 $q (paper)
024 7 $a 10.1007/978-981-19-3995-2 $2 doi
035 $a 978-981-19-3995-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC311.1 $b .P85 2022
072 7 $a MJ $2 bicssc
072 7 $a MED045000 $2 bisacsh
072 7 $a MJ $2 thema
082 0 4 $a 616.995 $2 23
090 $a RC311.1 $b .P982 2022
245 0 0 $a Pulmonary tuberculosis and its prevention $h [electronic resource] / $c edited by Takefumi Saito, Masahiro Narita, Charles L. Daley.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2022.
300 $a viii, 294 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Respiratory disease series: diagnostic tools and disease managements, $x 2509-5560
505 0 $a Part I. Epidemiology and Pathogenesis -- Chapter 1. Epidemiology -- Chapter 2. Immunology -- Chapter 3. Impact of Biologic and JAK Inhibitor Therapies on TB: How do Biologic Therapies Affect the Presentation and Treatment Course of Pulmonary TB? -- Chapter 4. Advances in Mycobacterial Laboratories: What is the latest laboratory approach to diagnose and manage pulmonary tuberculosis? -- Part II Pulmonary Tuberculosis -- Chapter 5. Advances in Diagnostics of Pulmonary tuberculosis: What is the Latest Approach to Diagnose Pulmonary TB? -- Chapter 6. HRCT diagnosis of pulmonary tuberculosis: Microlesions -- Chapter 7. Advances in Treatment of Drug Resistant Pulmonary TB: What is the latest approach to treat drug-resistant pulmonary TB? -- Chapter 8. The Role of Surgical Interventions for Pulmonary TB: What is the Role of Surgical Intervention in Pulmonary TB? -- Part III Latent TB Infection: TB Prevention -- Chapter 9. Advances in Diagnosis of Latent TB Infection: What is the Latest Approach to Diagnose Latent TB Infection to Prevent TB? -- Chapter 10. Advances in Treatment of Latent TB Infection: What is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB? -- Part IV Research Areas -- Chapter 11. TB vaccines: What Type of TB Vaccines are Studied and will be Available in the Future? -- Chapter 12. Clinical Trials of Pulmonary TB: Challenges and Opportunities -- Chapter 13. Contributions of Japanese Scholars to Advances in Clinical Tuberculosis Management: In TB World, What Kind of Achievements are Accomplished by Japanese Researchers?
520 $a Every year, 10 million people fall ill with tuberculosis (TB) in the world, and of those, 1.5 million people die even though it is a preventable and curable disease. As a result, TB remains the world's leading infectious cause of death. On the other hand, in industrialized countries, the TB incidence has fallen to a historic low, and clinicians' experience with TB diminished significantly in recent years. Additional challenges for clinicians include atypical presentation of TB in the immunocompromised, especially among the elderly, and an increasing number of patients with drug-resistant TB. Delayed diagnosis of TB leads to the spread of TB including nosocomial transmission because TB is an air-borne infectious disease, and suboptimal treatment can result in development of drug resistance. Furthermore, treatment of latent TB infection (LTBI) can prevent future TB cases but it has been under-utilized despite recent innovations in diagnosis and treatment regimens of LTBI. This book focuses on advances in diagnostic tools and treatment for both TB disease and latent TB infection. Each chapter/topic is written by one of the top TB experts in the field and the authors are from Japan and the US. Pulmonary Tuberculosis and its Prevention offers up-to-date information that can be incorporated into a busy practice of clinicians while they can appreciate broad international perspectives and gain in-depth knowledge on TB.
650 0 $a Tuberculosis. $3 808530
650 0 $a Tuberculosis $x Prevention. $3 842179
650 1 4 $a Internal Medicine. $3 858559
700 1 $a Saito, Takefumi. $3 3607962
700 1 $a Narita, Masahiro. $3 3607963
700 1 $a Daley, Charles L. $3 3607964
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Respiratory disease series: diagnostic tools and disease managements. $3 3297837
856 4 0 $u https://doi.org/10.1007/978-981-19-3995-2
950 $a Medicine (SpringerNature-11650)